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Four hundred and sixty nine patients were randomized to receive either 12pg bd of eformoterol (Oxis@, Astra 
Pharmaceuticals Ltd., Kings Langley, U.K.) delivered via Turbohaler@ or 50 pg bd salmeterol (Serevent@, 
Glaxo-Wellcome Ltd., Uxbridge, U.K.) via either the Accuhaler@ (Glaxo-Wellcome Ltd.) or pressurized metered 
dose inhaler (pMD1, Glaxo-Wellcome Ltd.) for 8 weeks. This was followed by a 4-week cross-over period when 
patients who had received salmeterol in the previous 8 weeks were given eformoterol and patients who had received 
eformoterol were given either salmeterol via the Accuhaler@ or pMD1 to assess patient device and treatment 
preference. 
For the primary efficacy variable, the increase in peak expiratory flow (PEF) rate from run-in to 8 weeks, similar 
significant improvements were seen in all three treatment groups. Eformoterol Turbohaler@ (FT) achieved a greater 
increase in morning PEF than salmeterol Accuhaler@ (SA) from randomisation to 4 weeks; the increase shown in 
the eformoterol Turbohaler@ group was 28.9 1 min - ’ compared to 19.9 1 min - ’ for the salmeterol Accuhaler@ 
group. The addition of eformoterol Turbohaler @ 12pg bd, to patients’ existing asthma therapy was found to have 
a significantly more beneficial effect on the severity of patients’ daytime asthma symptoms than had salmeterol 
Accuhaler@ 50,ug bd (P=O.O14). Eformoterol Turbohaler @ reduced the severity of daytime asthma symptoms by 
42% after only 4 weeks of treatment. The patients in the eformoterol Turbohale@ treated group experienced a 
higher percentage of days when they were symptom-free and did not use their short-acting bronchodilator to relieve 
symptoms (32.8, 24.1 and 28.0% in the FT, SA and SM groups, respectively). At 8 weeksthere were no significant 
differences in any of these variables between the three groups. 
Patients in all the treatment groups gained an additional l-l.5 nights undisturbed by asthma per week. The 
changes in sleep disturbance were not significantly different between the three treatment groups. 
In addition to the therapeutic benefits provided by eformoterol Turbohaler@ the device (Turbohale?) was the 
significant preference of patients given both Turbohaler@ and pMD1 (P=O.O168) and was also considered to be 
significantly more convenient to carry around than the Accuhaler@ (P<O.OOOl). No other differences were found 
between the three devices. 
The results of this study demonstrate that the addition of a long-acting &-agonist is an effective tool for achieving 
the goals of asthma treatment. Eformoterol via the Turbohaler@ is at least as effective as salmeterol via either the 
Accuhaler@ or the pMD1 in achieving these goals. 
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Introduction 
The use of inhaled short-acting &agonists in the manage- 
ment of asthma is well established and guidelines for their 
use (1) have been widely accepted (2). The short duration of 
action of these drugs at their recommended doses (4-6 h) is 
in many patients not adequate, particularly if nocturnal 
symptoms are present (3). The development of long-acting 
inhaled bronchodilators may offer improved therapy for 
these patients. 
Eformoterol is a bronchodilator with a long duration of 
action and a high selectivity for &receptors (4,5). Single 
dose studies in man, with eformoterol delivered via a 
pressurized aerosol metered dose inhaler (pMD1) demon- 
strate that eformoterol is a potent bronchodilator with a 
rapid onset of action of 1 min (6,7) and a duration of action 
of at least 12 h (8). Eformoterol 12 mg bd delivered via an 
inspiratory flow driven, dry powder inhaler (Turbohaler@, 
Astra Phamaceuticals Ltd., Kings Langley, U.K.) has been 
studied in a number of trials and has been shown to be 
more effective than either the short-acting &agonist 
terbutaline 0.5 mg qid or placebo in improving morning 
PEF, evening PEF and reducing daytime and night-time 
asthma symptoms (9). 
Salmeterol (Serevent5, Glaxo-Wellcome Ltd., Allen and 
Hanburys Ltd., Uxbridge, U.K.), the most widely pre- 
scribed long-acting &agonist, is a partial agonist with a 
relatively low affinity for the receptor which also remains 
bound to the receptor for a long period (10). Eformoterol in 
contrast is a more complete agonist which is believed to 
derive its long action from entering the cell membrane 
lipid bilayer and leaching out over a period of time (10). 
Eformoterol also differs from salmeterol in its faster onset 
of action (6,7). 
Previous studies have compared salmeterol and eformot- 
erol where both drugs are delivered via pMD1, and found 
that the bronchodilatory effects of these drugs are very 
similar (7). Comparisons of short-acting bronchodilators 
delivered via pMD1 or Turbohaler@ have demonstrated 
a greater efficacy for the Turbohale@ device (11,12). 
Salmeterol is available either in a pMD1 or in the 
Accuhaler@ (known as the Diskus@ in the Republic of 
Ireland) dry powder device (Glaxo-We&come Ltd.). 
This study compared the efficacy of eformoterol 
TurbohalerB 12 pg bd versus salmeterol.50 ,ug bd, delivered 
either by pMD1 or Accuhaler@, in the management of 
asthma in patients requiring a long-acting bronchodilator. 
The primary objective of this study was to compare 
the efficacy of eformoterol Turbohale@ 12 mg bd and 
salmeterol 50 mg bd, delivered either by pMD1 or 
Accuhaler@, in the management of asthmatics who have a 
clinical need for long-acting inhaled &agonist, based on 
the difference from baseline to 8 weeks in morning PEF as 
recorded in diary cards. 
The secondary objectives were to compare patient pref- 
erence fordrug/device assessed using a questionnaire. From 
the patients’ diary card entries to compare the differences 
in additional short-acting bronchodilator usage, daytime 
symptoms and nocturnal disturbances and the number of 
days patients were unable to attend work/school or perform 
normal daily activities due to asthma. Differences in any 
worsening of asthma which required a change in treatment 
recorded on patients’ diary cards and/or in medical records 
were also compared. 
Patients and Methods 
PATIENTS 
Patients aged 12 years and over were recruited from 110 
general practice and two hospital centres in the U.K. and 
Republic of Ireland. Multi-Centre Research Ethics com- 
mittee and Local Research Ethics Committee approval was 
gained for the study at each centre. Each patient gave 
written informed consent prior to participation in the study. 
For inclusion, patients were required to have a docu- 
mented diagnosis of asthma and have been receiving at least 
200 pug day - ’ inhaled steroid at a constant dose for at least 
the 4 weeks prior to entering the study. In addition the 
patients must have been using a short-acting &agonist as 
required and in the opinion of the investigator have a 
requirement for the addition of a long-acting &agonist. 
Patients were ineligible for the study if they had signifi- 
cant disease past or present or clinically relevant laboratory 
result which, in the opinion of the investigator, would 
interfere with the study. Those with documented or sus- 
pected diagnosis of irreversible chronic airways obstruction 
as judged by the investigator were also excluded. A PEF 
~50% of predicted, a respiratory tract infection (RTI) 
within the previous 4 weeks which required treatment with 
antibiotics, current beta-blocker therapy (eye drops 
included), a requirement for oral steroids or nebulised 
therapy, use of long-acting &agonists in the 4 weeks prior 
to entry into the study, hypersensitivity to &agonists or 
inhaled lactose, introduction of regular treatment with 
nasal corticosteroids and antihistamines (oral and topical) 
in the 4 weeks prior to visit 1, introduction of regular 
anti-inflammatory treatment for asthma (e.g. inhaled corti- 
costeroids, nedocromil, sodium cromoglycate, leukotriene 
antagonists) in the 4 weeks prior to visit 1, treatment with 
astemizole within 8 weeks prior to visit 1 or during the 
study, treatment with oxitropium or ipratropium bromide 
within 8 h prior to visit 1 or during the study, treatment 
with theophylline (xanthine) within 48 h (if once daily) or 
24 h (if twice daily) prior to visit 1 or during the study, 
regular treatment with immunotherapy at a constant dose 
for less than 12 weeks prior to visit 1, inability to use peak 
flow meter, Turbohaler@ , Accuhaler@ and pMD1 correctly 
after instruction, alcohol, drug or substance abuse or any 
confirmed or suspected condition associated with poor 
compliance, pregnancy, risk of pregnancy and breast feed- 
ing, previous randomization into this study or participation 
in any other clinical study of any investigational drug in the 
previous 16 weeks were also exclusion criteria. 
Patients were randomized into the study on fulfilment of 
the following criteria: a need for the addition of long-acting 
&agonist demonstrated by either a diurnal variation of at 
least 10% in PEF on at least 4 of the last 7 days during the 
run-in period or use of short-acting &agonist at least twice 
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a day on 4 out of the last 1 days during the run-in period. 
In addition patients were required to demonstrate an 
increase in PEF from before to after inhalation of a short- 
acting P,-agonist which was equal to or greater than 15% or 
an increase which is equal to or greater than 9% of 
predicted normal either documented in the patient’s notes 
or demonstrated at entry or randomization. 
STUDY DESIGN 
The treatment period was preceded by a run-in of 7-14 days 
during which baseline values could be established. Follow- 
ing completion of the run-in eligible patients were blindly 
randomized (visit 2) to receive either 12pg bd of eformot- 
erol (Oxis@, Astra Pharmaceuticals Ltd.) delivered via 
Turbohale@ or 50 pg bd salmeterol (Serevent@, Glaxo- 
Wellcome Ltd.) via either the Accuhaler@ or pMD1 in a 
ratio of 2:l:l for 8 weeks. This period was followed by a 
4-week cross-over period when patients who had received 
salmeterol in the previous 8 weeks were given eformoterol 
and patients who had received eformoterol were given 
either sahneterol via the Accuhaler@ or pMD1 in a ratio of 
1:l to assess patient device and treatment preference. The 
code envelope opened upon randomization at visit 2 gave 
details of both the treatment/device the patient was to 
receive during the first 8 weeks and the treatment/device the 
patient would receive after the cross-over. 
METHODS 
At entry patients continued with their current asthma 
medication at a constant dose. 
Patients completed a diary card twice daily for their 
entire time in the study when they recorded morning and 
evening peak expiratory flow (PEF) measurements (best of 
three attempts), grade of daytime and night-time symptoms 
(Grades: O=no symptoms; 1 =symptoms, but they do not 
affect any activities during the day or sleep at night; 
2=symptoms which affect at least one daily activity or 
disturb sleep; 3 = symptoms which affect two or more daily 
activities or disturb sleep all night or most of the night), 
how many times they used their reliever inhaler (short- 
acting bronchodilator) as prophylaxis or to relief symp- 
toms, use of reliever inhaler in the 6 h before taking their 
peak flow reading (Yes or No), whether they had taken 
their study medication as instructed (Yes or No) and 
indicated any days on which they were unable, as relevant, 
to attend work/school or perform normal daily activities 
due to their asthma. 
At each clinic visit patients discussed and graded their 
asthma symptoms - cough, wheeze, breathlessness and 
chest tightness according to the O-3 scale described earlier. 
Peak expiratory flow (PEF) was measured with a Vitalo- 
graph@ (Vitalograph Ltd., Buckingham, U.K.) absolute 
scale peak flow meter one of which was supplied to each 
patient at entry (visit 1) and used throughout the study. 
There was a 4-week interval between each of the remain- 
ing study.visits. 1 
At the final study visit patient inhaler preference was 
assessed using a questionnaire. 
Data on adverse events were collected at each clinic visit 
based on symptoms observed at the visit, the patient’s 
response to a question about health problems since the last 
visit and information recorded on the diary card or in the 
medical records since the last visit. 
ANALYSES _) 
All efficacy data were analysed by. the all patients treated 
(APT) approach. 
The study had a power of 90% to detect a clinically 
relevant difference of 20 1 min - ’ in the primary efficacy 
variable (morning PEF). Four hundred and sixty-nine 
patients were randomized into the study providing sufficient 
numbers to detect significant differences at the 5% level. All 
analyses were performed using SAS for Windows V. 6.12. 
The number of patients randomized at each centre was 
considered to be too small to test for centre effects, and 
therefore all analyses represent pooled results across all 
centres. 
All efficacy analyses were based on the comparison of 
the three treatment groups, eformoterol Turbohale@, 
salmeterol Accuhaler@ and salmeterol pMD1, unless 
otherwise stated. The groups refer to the treatment/device 
the patient received during the first 8 weeks of the study. 
The primary endpoint for analysis was 8 weeks. Diary 
card data from the last 7 days of the run-in period and 
the 7 days prior to the 8-week clinic visit were used in the 
analysis. The diary card variables were summarized by the 
number of occurrences (nocturnal wakening) or averages 
over each 7-day period (morning and evening PEF and 
symptom scores). Patients were required to have at least 4 
days of complete data during each 7-day period to be 
eligible for analysis. The change from baseline to 8 weeks in 
each of the following diary card assessments was analysed 
between treatment groups by one-way analysis of variance 
(ANOVA): morning PEF, evening PEF, sleep disturbance 
and daytime symptom severity. Morning and evening PEF 
were also analysed in terms of the percentage change from 
baseline. This analysis was repeated with a secondary 
endpoint of 4 weeks. Data from the last 7 days prior to the 
4 week clinic visit were used in this analysis. In the above 
analyses each ANOVA model included the baseline data as 
a covariant and the treatment group as a factor. 
The change from baseline to 4 and 8 weeks in the diary 
card assessments were analysed within groups by the 
Wilcoxon signed-rank’s test. 
Patient preference for drugs/devices recorded at 12 weeks 
was analysed by the sign test. 
The analysis of preference data was performed on two 
separate patient subgroups: one comparison comparing 
eformoterol Turbohale@ with salmeterol Accuhalera and 
one comparison comparing eformoterol Turbohale@ with 
salmeterol pMD1. 
The percentage of days with no symptoms and no use of 
short-acting bronchodilator to relieve symptoms during the 
first 8 weeks of treatment was analysed by one way 
ANOVA. A successful day was defined as one with no sleep 
disturbance, grade 0 night and day symptoms, no .use of 
short-acting bronchodilator during the day to prevent 
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TABLE 1. Demographic details/asthma history/baseline PEF 
Eformoterol Salmeterol 
TurbohalerB Accuhaler@ 
Salmeterol 
pMD1 
Demographic features 
Patients (n) 
Sex (M:F) 
Age (years) 
Weight (kg) 
Height (cm) 
Smoking status: n(%) 
Never 
Past 
Current 
If current, - g week ’ 
230 119 111 
84:146 53:66 48:63 
40.3 f 16.0 40.4 Et 17.5 39.9 rk 15.9 
73.2 3~ 16.8 74.2 f 17.7 74.0 f 15.0 
166.8 f 9.4 167.8 f 9.9 166.9 + 9.5 
110 (48) 57 (48) 54 (49) 
64 (28) 38 (32) 31 (28) 
56 (24) 24 (20) 26 (23) 
61.9 + 47.7 58.8 i 41.4 61.7 f 39.9 
Asthma history 
Length of asthma history: n(%) 
<l yr 
l-5 yrs 
5-10 yrs 
>lO yrs 
Baseline lung function 
50% predicted PEF (1 min - ‘) 
Mean f SD 
Entry (visit 1) 
PEF (1 min- ‘) 
Mean & SD 
Randomization (visit 2) 
PEF (1 min - ‘) 
Mean Z! SD 
5 (2) 4 (3) 4 (4) 
71 (31) 29 (24) 33 (30) 
42 (18) 25 (21) 22 (20) 
112 (49) 61 51) 52 (47) 
256.3 zk 36.9 260.6 f 39.7 260.0 zt 38.5 
371.8 f 92.2 376.6 AC 102.8 369.2 zk 92.1 
373.8 f 94.5 384.9 Y!Z 100.1 372.1 f 94.0 
Data are shown as number, proportion or percentage of APT patients in each group or as 
mean f SD. 
symptoms and no use of short-acting bronchodilator during 
the day or night to relieve symptoms. 
Morning, evening and clinic PEF were analysed in terms 
of the percentage change from baseline, in addition to the 
absolute change pre-specified in the study protocol. 
In the analyses of the change in diary card assessments 
and the change in clinic assessments from baseline to 4 and 
8 weeks, each ANOVA model included the baseline data as 
a covariate and the treatment group as a factor. 
The P-values for between treatment comparisons were 
obtained from pairwise comparisons specified in the 
ANOVA analysis. 
The significance level of the between treatment compari- 
sons was adjusted for multiple comparisons. The preference 
questionnaire was adjusted for two comparisons (FT vs. SA 
and FT vs. SM), and a P-value less than 0.025 corresponded 
to a statistically significant result. All other between treat- 
ment comparisons were adjusted for three comparisons (FT 
vs. SA, FT vs. SM and SA vs. SM), whereby a statistically 
significant result corresponded to a P-value less than 0.017. 
The level of significance for the within group analyses was 
not adjusted and thus a P-value less than 0.05 represented a 
significant change from baseline. 
Results 
A total of 600 patients were enrolled into the study, of 
whom 469 were randomized at visit 2. Of the 131 patients 
discontinuing prior to randomization, 51 failed to fulfil the 
randomization criteria, 25 had PEF readings of ~50% 
predicted, 25 had insufficient reversibility, 11 failed to 
return for visit 2, eight had incomplete diary card data, six 
failed the inclusion criteria, three had adverse events 
(including one patient whose asthma deteriorated), one 
patient was withdrawn due to incorrect asthma medication 
use and one due to unavailability of study drugs at centre. 
Nine patients were excluded from the APT population due 
to no assessment of efficacy after randomization or due to 
the patient taking no study medication. The APT popula- 
tion comprised 230 patients who received eformoterol 
Turbohale@ (FT) dur’ g m weeks 1-8, 119 patients who 
received salmeterol Accuhaler@ (SA) and 111 patients who 
received salmeterol pMD1 (SM). Of the 230 patients receiv- 
ing eformoterol Turbohaler@ during period 1, 116 were 
randomized to receive salmeterol via the AccuhalerB 
after the cross-over and 114 were randomized to receive 
salmeterol via the pMD1. 
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FIG. 1. Change from run-in to 4 weeks in morning PEF 
(FT, e=formoterol Turbohaler’? SA, salmeterol ’ 
Accuhale@; SM, salmeterol pMD1; 0, baseline; I 
n , 4 weeks; P=O.OOOl for all treatments). 
E 1.4 - 
g 1.2 - 
E 3 l- 
l 
3 ;‘i- . 
i 0.4- 
0 0.2 - 
O- 
t-P = 0.0140 -1 
FT SA SM 
FIG. 2. Daytime asthma symptoms at baseline (Cl), 4 (m) 
and 8 (U) weeks (FT=eformoterol Turbohale@; 
SA=salmeterol Accuhaler@; SM=salmeterol pMD1; 
P=O.O168). 
The three treatment groups were comparable with 
respect to all patient demographic details at entry to the 
study (Table 1). The treatment groups were also well 
matched in relation to asthma history and baseline lung 
function. 
TREATMENT PERIOD 
Change from run-in to 8 weeks in morning PEF 
There was no evidence of a significant difference between 
the three treatment groups with respect to the change in 
morning PEF after 8 weeks’ treatment, both in terms of the 
absolute change and the percentage change (Table 2). 
Morning PEF increased by an average of 29.7 1 min - i, 
27.8 1 min - ’ and 32.11 min - ’ in the FT, SA and SM 
groups respectively. In terms of the percentage change from 
baseline, average improvements of 9.5, 8.7 and 10.7% were 
observed in the FT, SA and SM groups, respectively. 
Within all three treatment groups, both the absolute 
improvements and percentage improvements were 
statistically significant (all P=O.OOOl). 
FIG. 3. Percentage of patients expressing a preference 
when asked which inhaler [eformoterol Turbohalers 
(m) or salmeterol Accuhalers (O)] was more convenient 
to carry around (P<O.OOOl). 
FIG. 4. Inhaler preferred by patients when given the 
choice of eformoterol Turbohale@ (0) or salmeterol 
pMD1 (m) (P=O.O168). 
Change from run-in to 4 weeks in morning PEF 
The analysis of morning PEF was repeated at 4 weeks. 
Improvements of 28.9 1 min - ’ (9.3%), 19.9 1 min - ’ (6.5%) 
and 26.1 1 min - i (9.4%) were observed in the FT, SA and 
SM groups respectively. There was no evidence of a signifi- 
cant difference between treatments with respect to both the 
absolute change and percentage change in morning PEF 
from run-in to 4 weeks (Fig. 1). Within all three treatment 
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TABLE 3. Adverse events during the study with a reporting frequency of 25% 
System organ class 
adverse event 
Eformoterol Salmeterol Salmeterol 
Turbohale@ Accuhaler@ pMD1 
(n=422)* (n=217)* (n=209)* 
Patients with Patients with Patients with 
adverse events adverse events adverse events 
n (%) n (%) n (“33) 
Respiratory system disorders, total 
Respiratory infection 
Asthma aggravated 
Pharyngitis 
coughing 
Central and peripheral nervous 
system disorders, total 
Headache 
Body as a whole-general disorders, total 
Pain 
167 
74 
122 
22 
9 
44 
36 
71 
19 
W) 94 (43) 89 (43) 
(17) 38 (17) 40 (19) 
(28) 72 (33) 52 (25) 
(5) 7 (3) 17 (8) 
(2) (4) (5) 
(10) 1: (9) :; (8) 
(8) (5) (6) 
(17) :; (10) ii (13) 
(4) 5 (2) 11 (5) 
*Number of patients in treatment group. 
Total ‘n’ and ‘%’ refer to the total number/percentage of patients in the study who experienced an 
AE in each body class. Numbers not in bold represent the number of AEs of each given type. 
groups these improvements were statistically significant (all 
P=o~ooo1). 
Evening PEF, as recorded in daily diary cards 
Average improvements of 21.1 1 min-’ (6.5%), 15.0 1 
min - ’ (4.6%) and 25.8 1 min - ’ (8.3%) were observed in the 
FT, SA and SM groups, respectively, from run-in to 8 
weeks. No significant difference was found between the 
groups, however, the changes were clinically relevant and 
significant within all three groups. 
Daytime asthma symptoms [Fig. 2) 
The improvement in daytime symptom severity after 4 
weeks was significantly greater in the group of patients who 
received eformoterol Turbohale@, compared to those 
patients who received sahneterol Accuhaler@ ( - 0.54 vs. 
- 0.35; P=O*O140). There was no evidence of a difference in 
the change in daytime symptom severity between the FT 
and SM groups nor between the SA and SM groups. 
Sleep disturbance due to asthma 
Patients in all the treatment groups gained an additional 
l-l.5 nights undisturbed by asthma per week, observed in 
both the analyses after 4 and 8 weeks treatment. The 
changes in sleep disturbance were not significantly different 
between the three treatment groups. 
Patient preference questionnaire 
The Turbohale@ was significantly more convenient to 
carry around than the Accuhaler@ (P<O.OOOl), as illus- 
trated in Fig. 3. When asked which inhaler they would 
prefer to use given the choice, significantly more patients 
indicated that they would prefer to use the Turbohale@ 
rather than the pMD1 (P=O.O168), displayed in Fig. 4. No 
significant differences were found in the other comparisons 
between the devices. 
Percentage of days symptom-free and using no short-acting 
bronchodilafor to relieve symptoms 
The percentage of days on which the patients were 
symptom-free and did not use their short-acting broncho- 
dilator to relieve symptoms was calculated to be 32.8, 24.1 
and 28.0% in the FT, SA and SM groups, respectively. The 
differences between treatments were not statistically 
significant. 
WITHDRAWALS AND ADVERSE EVENTS 
Of the 469 randomized patients, 92 discontinued following 
randomization. Thirty-four (15%) from the eformoterol 
Turbohaler@ group, 17 (14%) from the salmeterol Accu- 
hale@ group and 19 (17%) from the salmeterol pMD1 
group discontinued on or before the end of their first 
treatment period. The remaining 22 discontinuations 
occurred after the patient had crossed-over treatment, 
15 while receiving eformoterol Turbohaler@, four while 
receiving salmeterol Accuhaler@ and three while receiving 
salmeterol pMD1. Six of these 22 patients were withdrawn 
because they had incorrectly crossed-over at the week 4 
clinic visit (4FT, 2SA). 
A total of 1171 adverse events were reported during the 
study (run-in and treatment period) by 390 patients. 
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TABLE 4. Worsening of asthma and subsequent changes in treatment during weeks l-8 for patients in each group 
Eformoterol Salmeterol 
Turbohale@ Accuhaler@ 
SalmeteroP 
pMD1 
Number of episodes of worsening of asthma 
Mean & SD 
n 
Min-Max 
Total number of episodes of worsening of asthma 
Number of patients with worsening of asthma: n (%) 
Number of episodes of worsening of asthma resulting in 
increase in inhaled steroid dosage 
Number of days 
Mean ZLZ SD 
n 
Min-Max 
Short course of oral or nebulised steroids 
Number of days 
Mean & SD 
n 
Min-Max 
>7 days of treatment 
Hospital admission/visit to A&E 
0.12 Lt 0.35 0.13 + 0.36 0.12 f 0.32 
230 119 111 
o-2 o-2 o-1 
28 15 13 
26/230 (11) 14019 (12) 13/111 (12) 
16 (57%) 10 (67%) 2 (15%) 
8.6 zt 8.0 6.3 zt 4.3 5 
14 6 1 
l-30 2-14 5 
13 (46%) 5 (33%) 11 (85%) 
5.5 f 2.0 8.3 f 3.2 5.5 k 1.8 
11 3 10 
3-10 6-12 l-7 
5 (18%) 3 (20%) 1 (8%) 
1 (4%) 1 (7%) 2 (15%) 
Number of episodes of worsening of asthma per patient: 
Eformoterol Turbohaler@ vs. salmeterol Accuhaler@: (0.12 vs. 0.13) P=O.9144; 
Eformoterol Turbohale@ V.Y. salmeterol pMD1: (0.12 vs. 0.12) P=O.9041; 
Salmeterol Accuhaler@ vs. salmeterol pMD1: (0.13 vs. 0.12) P=O.8416. 
Several patients reported more than one adverse event 
and hence the number of adverse events is higher, in some 
cases, than the number of patients reporting them. During 
the treatment period there were 526 adverse events from 
the 235 patients in the eformoterol Turbohale@ group(s), 
266 from the 120 patients in the salmeterol Accuhaler@ 
group(s) and 257 adverse events reported by the 113 
patients taking salmeterol pMD1. The given numbers are 
combined figures for both the first 8 weeks of treatment 
and the cross-over period. These numbers reflect the 
(2:l: 1) ratio of patients on eformoterol Turbohale@, 
salmeterol Accuhale@ and salmeterol pMD1 during the 
study. There were no apparent significant differences 
between treatment groups in the numbers of patients 
reporting adverse events in any body class. Table 3 details 
the adverse events with a reporting frequency of greater 
than or equal to 5%. Respiratory system disorders were 
reported by the highest percentage of patients in each 
group (FT: 40%, SA: 43%, SM: 43%). These were in the 
main asthma aggravations and respiratory infections. 
Although not significantly different from salmeterol, the 
eformoterol treatment would appear to provide patients 
greater protection from a deterioration in the disease 
under study (asthma) and associated respiratory condi- 
tions. The number of patients reporting nervous system 
disorders, notably headaches and tremor, was also 
relatively common. 
Discussion 
The British Thoracic Society guidelines clearly state that the 
purpose of asthma treatment is to abolish symptoms as 
soon as possible and optimize PEF (13). In this study the 
improvements seen emphasize the importance of long 
acting /?,-agonists in achieving these goals within current 
asthma management guidelines. 
During the dourse of the study there was an overall 
improvement in both PEF and asthma symptoms and a 
reduction in the use of short-acting P,-agonists recorded at 
clinic visits and on diary cards. 
The addition of eformoterol Turbohalera 12,~g bd to 
patients’ existing asthma therapy was found to have a 
significantly more beneficial effect on the severity of 
patients’ daytime asthma symptoms than salmeterol 
Accuhaler@ 5Opg bd had (P=O.O140). The eformoterol 
Turbohaler@ reduced the severity of daytime asthma 
symptoms by 42% after only 4 weeks of treatment. 
Also of note was that the level of PEF improvement 
(28.9 1 min - ‘) for the eformoterol treatment at 4 weeks is 
similar to that achieved by the salmeterol treatments after 
8 weeks. 
The patients in the eformoterol Turbohale@ treated 
group experienced a higher percentage of days when they 
were symptom-free and did not use their short acting 
bronchodilator (32.8, 24.1 and 28.0 in the FT, SA and SM 
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groups, respectively), although the differences did not reach 
statistical significance. 
Patients in all the treatment groups gained an additional 
l-l.5 nights undisturbed by asthma per week. The changes 
in sleep disturbance were not significantly different between 
the three treatment groups. 
In this study, when an episode of worsening of asthma 
resulted in a change of treatment, patients in the eformot- 
erol Turbohale@ and salmeterol Accuhaler@ groups were 
more likely to increase their inhaled steroid dose (FT 19%, 
SA 18% and SM 6% of the exacerbations treated in this 
way) whereas patients in the salmeterol pMD1 group were 
more likely to take a short course of oral or nebulised 
steroids (FT lS!!, SA 9% and SM 31% of the exacerbations 
treated in this way). These differences were not statistically 
significant. The record of worsening of asthma and subse- 
quent changes in treatment for patients in each group are 
given in Table 4. The choice of treatment and management 
of these episodes was left entirely to the physicians’ 
discretion. 
In this study in addition to the therapeutic benefits pro- 
vided by eformoterol Turbohale@ the device 
(Turbohale@) was the significant preference of patients 
given both Turbohaler@ and pMD1 (P=O.O168) and was 
also considered to be significantly more convenient to carry 
around than the Accuhaler@ (P<O.OOOl). 
In conclusion this study has shown that in asthma patients 
currently receiving inhaled steroids and still 
symptomatic the addition of a long-acting &agonist 
is an effective tool for achieving the goals of asthma 
treatment. At 4 weeks eformoterol via the Turbohale@ 
produces a more notable improvement in PEF and control 
of daytime asthma symptoms than salmeterol via the 
Accuhaler@. In addition, the Turbohale@ is more 
convenient to carry than the Accuhaler@ and easier to use 
than a pMD1. 
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